Five studies examined dysadherin in head and neck cancers (27–31), and three of them suggested high tumoral dysadherin mRNA expression or protein levels to predict poor overall survival (Table 1 and Supplementary Table 1). This evidence concerns the gene FXYD5 and head and neck cancer.